Vascular disorders are one of the largest causes of mortality and morbidity in women.
Despite this, women remain underrepresented in cardiovascular prevention studies partly due to the assumption that women will be largely protected against vascular diseases until postmenopause. 2 Furthermore, the distinct patterns of early disease development, particularly related to factors specific to women, such as pregnancy, remain poorly understood. [3] [4] [5] [6] [7] Nevertheless, from an early age women have a comparatively higher level of interaction with medical services than men because of their specific needs around reproductive health and prescription of oral contraceptives. There are also well-recognised associations between these factors and cardiovascular risk that might provide an opportunity for optimisation of cardiovascular prevention advice.
A key point of interaction that leads to increased awareness of hypertension in women is during routine health checks for contraceptive prescription. Regular checks of blood pressure are undertaken while the oral contraceptive is prescribed 8 and if high blood pressure is noted then current guidelines advise a review of oral contraceptive prescription with a change to progestin-only preparations to reduce risk. 9 In the current issue of the European Journal of Preventive Cardiology, Glisic et al. 10 have reviewed the evidence base for risk associated with use of progestin-only contraceptives. They argue that the type of progestin and route of administration has evolved over time, with greater use of depot preparations, and that there has been limited study on the overall effect of these preparations on a broad range of cardiometabolic outcomes. They used a systematic review and meta-analysis to bring together data from 19 studies that included over 60,000 women of which nearly 12,000 had used progestin-only contraceptives.
Their data provides robust and reassuring findings that indicate minimal or no effect on cardiometabolic profiles with use of these agents, when given orally. The rates of venous thromboembolism, myocardial infarction and stroke are almost identical to those seen in women not on the progestin-only preparations. Furthermore, there is no clear effect on blood pressure noted, supporting current guideline advice. 9 The only query they raise is in relation to injectable preparations. When studying the relatively small evidence base in the published literature in which cardio-metabolic outcomes had been compared in a group who had received injectable or depot preparations, they found increased rates of venous thromboembolism and potentially higher rates of diabetes.
The demographic profile of most of the included studies was focused around younger women and, as a result, the sum total of more severe events, such as stroke and myocardial infarction, is very low. These results are reassuring about short term effects but do not indicate whether there may be any effect on lifetime risk. The demographic spread also means rates of venous thromboembolism are higher than for other outcomes. Therefore the lack of impact of oral contraceptive use on thromboembolism risk is reassuring but, at the same time, suggests that the increased risk in those on injectables needs to be considered carefully. A weakness is the observational nature of the findings so that causality cannot be demonstrated. Underlying reasons why injectables were used is poorly reported and it is possible that confounding factors linked with higher cardiometabolic risk explain this association. The example the authors present is that, in one study, higher rates of injectable use occurred in women who had gestational diabetes and the higher rates of diabetes in this group was explained by the link with gestational diabetes. 11 To what extent injectables use varies with age and in different medical situations, such as postpartum or in those with previous pregnancy complications who may have higher cardiovascular risk, is also not considered in detail. Nevertheless, the nearly three-fold higher rate of venous thromboembolism suggests that identification of consistent factors that lead to injectable prescription in some women needs further investigation. This will help understand relevant risk factors and to explore the possibility that there is a real clinical risk associated with injectable use in this population.
Glisic et al. present a large scale and comprehensive review of cardiometabolic health in women taking progestin-only contraceptives. They provide robust data to suggest that oral progestin-only preparations have no overall impact on a range of cardiometabolic outcomes. These findings indirectly support guideline advice to use progestin-only contraceptives as a safer alternative in those women with increased cardiovascular risk, such as those with hypertension. However, the paper leaves a lingering concern around injectable use that requires further investigation. At present a 'right choice' is available but questions remain.
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